RxDoctor Payments Data

Svarit Dave, MD

Family Medicine · Louisville, KYNPI 1962795948

Payments from drug & device makers

$335in general payments, 2019–2025

Across 9 payments — averaging $37.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$125
  • Johnson & Johnson$104
  • Amgen$30
  • E.r. Squibb & Sons, L.L.C.$27
  • AbbVie$22
  • Novo Nordisk$16
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$30892%
  • Education$278%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$335 in reported general payments places this provider in the 35th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$119,910
Medicare patients
422
Services billed
1,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$118,592
OzempicSemaglutide56$67,868
MounjaroTirzepatide44$48,189
JardianceEmpagliflozin39$42,675
XareltoRivaroxaban29$36,480
JanuviaSitagliptin Phosphate22$29,335
TrulicityDulaglutide20$24,977
Repatha SureclickEvolocumab21$19,228
Breo ElliptaFluticasone/Vilanterol29$12,599
InvokanaCanagliflozin15$12,477
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,676
GemtesaVibegron15$9,348
Atorvastatin Calcium530$4,359
Metoprolol Succinate169$2,879
Levothyroxine Sodium275$2,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$67,86856 claims
Johnson & JohnsonXarelto, Invokana$104$48,95744 claims
Boehringer IngelheimJardiance$11$42,67539 claims
AbbVieSynthroid$22$1,72350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →